Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane By Ogkologos - July 6, 2026 111 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOFT and TEXT studies Source RELATED ARTICLESMORE FROM AUTHOR Five-Year Survival Outcomes with Neoadjuvant Therapy in Melanoma Demonstrate that Neoadjuvant ICIs Exceeded Adjuvant Benchmarks Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib MOST POPULAR Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or... March 3, 2025 New on NCI’s Websites for September 2021 September 1, 2021 FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications December 10, 2021 Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia July 13, 2021 Load more HOT NEWS Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage...
